Past Projects
Policy Impact Analysis
Impact Assessment of Policy Options for Strengthening EU Cooperation on Health Technology Assessment (HTA) - European Commission (2016-2018).
In this EU funded project, I assessed the potential impact of different options for collaboration on HTA and health technology procurement within Europe. The aim of this project was to understanding the existing cost of HTA across Europe (both in terms of human and physical resources), the extent to which effort was being duplicated across settings (at both public and private sector level), and whether collaborative HTA initiatives would provide value.
EFPIA HTA Toolkit - European Federation of Pharmaceutical Industries and Alliances (2019-2021)
In this project, I helped develop a comprehensive HTA toolkit for the European Federation of Pharmaceutical Industries and Alliances, spanning all dimensions of HTA including Horizon Scanning, Scientific advice, Governance, Timelines, Fees, Clinical Evidence Assessment, Economic Evidence Assessment, Social Value Considerations, Risk-sharing tools, and Dissemination.
IMPACT HTA WP7 - Horizon 2020 (2018-2019)
IMPACT HTA is an EU funded Horizon 2020 project, which aimed to to understand variations in the assessment of costs and benefits of health technologies across settings and to provide actionable tools and methodological improvements in the conduct of HTA for EU member states. Through LSE, the consortium leader for IMPACT HTA, I was involved in Work Package 7 of this initiative, which involves an assessment of the determinants of HTA decision-making across settings and development of a multi-dimensional value framework. https://www.impact-hta.eu/
Training and Capacity Building
Principles of HTA workshop - Abu Dhabi Department of Health (2022 - present)
This course, involving a series of webinars and in-person workshops, is designed to train participants in the implementation of HTA, including clinical evidence assessment, economic evidence assessment, and appraisal and decision-making. The course was initiated in December 2022 and will run until July 2023, with the aim of assisting the department of health in establishing an HTA unit for the evaluation of health technologies. I co-developed the materials for this course and I am leading the delivery of workshops and webinars.
WHO Medicines Strategic Procurement Workshop with a focus on negotiations - WHO Europe (2017-2018)
This series of workshops with WHO Europe was designed to provide EU member states with training on the principles of negotiation in the context of pharmaceutical. The workshops were attended by representatives from over 20 EU member states. My role included lecturing, development of case study materials and case study facilitation.
Financing High Cost Therapies - Novartis (2019-2020)
In this project, I evaluated financing options for high cost curative therapies. Technologies such as cell and gene therapies, which are often times single use therapies, tend to have high up-front costs, uncertain evidence bases, and benefits that accrue over a patients life time. This work involved an assessment of the key challenges presented by curative therapies, an overview and assessment of the different approaches currently employed by different settings, and recommendations for future reform.
BCG-LSE Market Access Academy - London School of Economics and Political Science Executive Education (2017 - present)
The BCG-LSE Market Access Academy is a week long executive education programme held at the LSE targeting future market access leaders in the pharmaceutical sector. Participants must have a minimum of 5 years experience working in the private sector. The course involves a mix of lectures and case study work relating to market access of pharmaceuticals. I have been a course teacher on several workshops dating back to 2017, leading the delivery of the case study work.
